Genentech will no longer be producing Nutropin AQ ® (somatropin) NuSpin ® formulations due to a combination of business considerations and the availability of alternative growth hormone options for ...

Growth hormone treatment is a safe and effective therapy that’s often used to treat children and adults with a deficiency in human growth hormone (also known as HGH or somatropin). Naturally-occurring ...

Sogroya is a long-acting form of somatropin. Somatropin is also called human growth hormone. Sogroya is made by attaching human growth hormone to a small protein that helps it stay in the body longer ...

March 5, 2010 — The US Food and Drug Administration (FDA) has approved a prefilled somatropin (rDNA origin) injection pen (Norditropin FlexPro, Novo Nordisk, Inc) for the treatment of growth hormone ...

Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya (somapacitan) in four different but related growth disorder indications, ...

A Prescription Drug User Fee Act target date of July 27, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License ...

The FDA approved long-acting injectable somatrogon (Ngenla) for pediatric human growth hormone deficiency, developers Pfizer and OPKO Health announced this week. Somatrogon is indicated for children ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved long-acting once-weekly somatrogon for children with growth hormone deficiency. Somatrogon was ...

(RTTNews) - Swiss biopharmaceutical company Ascendis Pharma A/S (ASND) announced Monday that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA (lonapegsomatropin-tcgd; developed as ...

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...